Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
GFH276 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
GFH276: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
UCL-70802 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
UCL-70802: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Human cord derived MSC cell(S-Evans Biosciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Human cord derived MSC cell(S-Evans Biosciences): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
Homologous Allogeneic Hepatocytes(Renji Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Homologous Allogeneic Hepatocytes(Renji Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
TRX-103 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
TRX-103: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Autologous Tumor-Infiltrating Lymphocytes(Essen Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Autologous Tumor-Infiltrating Lymphocytes(Essen Biotech): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
KD01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
KD01: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BY-101921 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
BY-101921: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
GC-301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
GC-301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HB-0043 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
HB-0043: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
VTx 002(VectorY Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
VTx 002(VectorY Therapeutics): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EB-CAR30-NK (Beijing Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
EB-CAR30-NK (Beijing Biotech): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.